Navigation Links
EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Date:8/20/2007

LYON, France, Aug. 17 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, is currently conducting clinical investigations in France under an approved clinical trial combining the company's Ablatherm-HIFU device with chemotherapy using docetaxel.

The study is a primary treatment therapy program for men suffering from clinically localized but aggressive high risk prostate cancer typically classified as stage T2c. The study began in late 2006 and will enroll a total of 30 men, of which more than 10 have already been treated.

"Combination therapy is well documented as a treatment protocol for men suffering more aggressive prostate cancers," said Dr. Albert Gelet, Edouard Herriot Hospital, Lyon. "Ablatherm-HIFU is a proven effective treatment for localized prostate cancer already with strong clinical support. This study aims to evaluate its use under an additional dedicated protocol for men in the T2c cancer stage where the tumors are known to be more aggressive, creating a higher risk of relapse if the patient is treated with only a localized therapy. It was demonstrated in pre-clinical studies that HIFU improves chemotherapy drug efficacy in the area around burned tissues."

Under the approved protocol by French Ethical Committee, patients are administered a dose of docetaxel 30 minutes prior to a standard primary indication HIFU session lasting an average of two hours. The Ablatherm-HIFU ablates the prostate tissue according to conventional procedures and protocols. All treatments are administered at Edouard Herriot Hospital in Lyon, France.

"EDAP has a strong scientific and clinical base underlying the Ablatherm-HIFU, with constant work to enhance and extend the capabilities of the device," said Pr John Rewcastle, Medical Director for EDAP. "With already well documented specialized protocols for primary therapy, HIFU retreatment and salvage th
'/>"/>

SOURCE EDAP TMS S.A.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... JUPITER, Fla. , Aug. 3, 2015 /PRNewswire/ ... announced initiation of its second clinical development program ... drug candidate, CL-H1T.  CL-H1T contains ... is being developed as a treatment for migraine ... "Many patients with migraine headaches ...
(Date:8/3/2015)... and FLORHAM PARK, N.J. , ... once-daily naldemedine met its primary and secondary endpoints in ... of opioid-induced constipation (OIC) in adult patients with chronic ... mu-opioid receptor antagonist (PAMORA). This is the third Phase ... key secondary endpoints. Study results showed that ...
(Date:8/3/2015)... ZIONA, Israel , August 3, 2015 /PRNewswire/ ... today announced it received the statistical analysis of results from ... administered in the BVX-005 phase II trial which took place ... which did not exist at the time of the study- ... that caused the epidemic in the United States ...
Breaking Medicine Technology:Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
(Date:8/3/2015)... ... August 03, 2015 , ... ... 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb B2B Awards ... brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics product was ...
(Date:8/3/2015)... ... 03, 2015 , ... To date, many pharmaceutical and biotech ... of benefits, allowing them to gain access to capabilities that cannot be found ... resources, get access to innovation and ensure timely introduction of product into the ...
(Date:8/3/2015)... ... August 03, 2015 , ... A recent survey by ... of Hispanics believe people can positively affect their diabetes, few look beyond diet ... making diet changes was important. Far fewer participants mentioned the need for exercise ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... and the largest online retailer of nutritional supplements, has officially opened the ... for 11 awards in the following categories:, ,     Brand ...
(Date:8/3/2015)... Venice Beach, CA (PRWEB) , ... August 03, ... ... supporting individuals suffering from ALS and amputation , AUGUST 3, 2015 – Since ... DIY category in March 2015, Not Impossible – an organization whose mission is ...
Breaking Medicine News(10 mins):Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4
... Kentucky Ranks 47th Nationwide in Health Status; Anthem Blue ... services to more than 5,000, Kentuckians located in ... LOUISVILLE, Ky., Nov. 14 Anthem Blue Cross and ... program that,incorporates public health data to identify and help ...
... in with a strong,70% Omega-3 fatty acid content, ... formula, is now available in convenient,smaller-sized soft gels. ... same exceptionally high concentrated oil as Ultimate Omega, ... swallowing. Ideal for ages 5,through adult, the all ...
... FORT MYERS, Fla., Nov. 14 NeoGenomics, Inc.,(OTC Bulletin ... its results for the third quarter of FY 2007.,Significant ... nine,months of the year included the following: Third ... revenues in Q3 07 vs. Q3 06 -- ...
... Ill., Nov. 14 Delta Dental, the nation,s,largest ... Readers,Choice Award from Benefits Selling magazine as the ... and network availability. The,awards were announced in the ... Selling surveys its readers annually, asking them to ...
... reporting the first successful strategy to reduce smokers nicotine ... study provides strong support for proposals now being considered ... according to the research team. , The key to ... of gradually decreasing nicotine content over a number of ...
... 14 On the first United Nations World,Diabetes ... to develop national policies for the prevention, care ... to consider the need,for a diabetes global fund ... at the World Diabetes Day press conference, Dr ...
Cached Medicine News:Health News:Anthem Blue Cross and Blue Shield in Kentucky Announces Release of State Health Index 2Health News:Anthem Blue Cross and Blue Shield in Kentucky Announces Release of State Health Index 3Health News:Anthem Blue Cross and Blue Shield in Kentucky Announces Release of State Health Index 4Health News:Nordic Naturals Introduces Ultimate Omega 500 - Their Best Selling Formula Now Available in a Smaller Size Soft Gel! 2Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 2Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 3Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 4Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 5Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 6Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 7Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 8Health News:Brokers Name Delta Dental the Best in Coverage, Plan Design and Networks 2Health News:Nicotine addiction slashed in test of new cigarette smoking strategy 2Health News:Nicotine addiction slashed in test of new cigarette smoking strategy 3Health News:First United Nations World Diabetes Day Unites Global Diabetes Community to Fight the Epidemic 2Health News:First United Nations World Diabetes Day Unites Global Diabetes Community to Fight the Epidemic 3Health News:First United Nations World Diabetes Day Unites Global Diabetes Community to Fight the Epidemic 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: